We are committed to developing first and best-in-class therapeutics for patients with high unmet need across a wide range of diseases.

We aim to discover and develop innovative therapeutics across a broad range of diseases to realize the transformative potential of previously undruggable targets. We are advancing an internal pipeline of programs in rare genetic diseases, immune-mediated diseases and oncology. Collaborations with biopharma partners are a critical part of our strategy, giving us additional opportunities to leverage theĀ RAPID platform to address patient needs, including in therapeutic areas outside of our current internal focus.

Jnana is advancing a robust pipeline of novel therapies across rare diseases, immunology and oncology.


Back to Top

This links to an external website. Merus is not responsible for any third party content.